Get In Touch

As a consequence of the pandemic of type 2 diabetes, an outbreak of several diabetic complications, particularly diabetic retinopathy is foreseen by several healthcare institutions and pharmaceutical companies across the globe. Among complications of diabetic retinopathy, proliferative diabetic retinopathy has witnessed a relatively more significant surge worldwide. For example, roughly 1.5% adults suffering from diabetes were affected from proliferative diabetic retinopathy in the U.S. in the recent past.

Although molecular and cellular bases of the proliferative diabetic retinopathy have only been partially understood, complication of diabetes is evidently characterized by formation of new vessels inside retina that depicts abnormal architecture and permeability. Angiogenesis is considered to have a major role in pathogenesis of proliferative diabetic retinopathy, with intravitreal antiangiogenic injection being suggested by researchers and drug developers as a viable treatment for the disease. Different antiangiogenic approaches are being employed for developing effective treatment of proliferative diabetic retinopathy, which in turn are likely to have imperative roles for therapy & prevention of the disease in the upcoming years.

global proliferative diabetic retinopathy market

A recently composed research report of Transparency Market Research has envisaged the global market for proliferative diabetic retinopathy to register a high single-digit CAGR through the forecast period (2017-2026). Revenues from treatment of proliferative diabetic retinopathy around the world are poised to reach roughly US$ 1,000 Mn by 2026-end.

Anti-VEGF Considered as Effective Management Method for Proliferative Diabetic Retinopathy

According to the National Center for Biotechnology Information (NCBI), over 150 Mn individuals were affected by diabetic retinopathy globally, with majority of them at the risk of developing proliferative diabetic retinopathy. Such rapid rise in the number of people with this diseases will increase the scope of its treatment & prevention. Across countries with relatively less availability of treatment facilities, demand and supply of effective treatment drugs have been witnessing a tremendous surge.

Recent studies suggest high level of the vascular endothelial growth factor (VEGF) being detected in fibrovascular tissues of eyes of diabetic patients has prompted use of anti-VEGF as the most effective and efficient management method, in cases of proliferative diabetic retinopathy. Introduction and robust adoption of the intravitreal pharmacologic agents, especially drugs that inhibit actions of VEGF, have directed the focus of approach toward proliferative diabetic retinopathy treatment from vision stabilization to improvement. Improvements in visual acuity of patients with this diseases by using anti-VEGF are comparatively more effective than improvements observed in treatment by using corticosteroids.

Growth in Geriatric Population to be a Key Demand Determinant of Drugs for Proliferative Diabetic Retinopathy Treatment

Geriatric populace across the globe has been exhibiting a significant increase, and this demographic group is highly susceptible to various chronic disorders such as diabetes. Proliferative diabetic retinopathy development is therefore more prevalent among the elder individuals. Cases of this diseases are deemed to be multifold in patients who are above 65 years old and have a diabetic history. This has further driven the demand for effective drugs for management of proliferative diabetic retinopathy in older population.

The rise in disposable income of consumers, coupled with concerns regarding vision loss has rubbed off on spending by patients for availing necessary treatment of diabetic retinopathy. Availability of advanced technology & minimally invasive laser technique that complements faster recovery time is likely to encourage willingness of patients affected from proliferative diabetic retinopathy in adopting surgical treatments.

Key companies significantly contributing to growth of the global proliferative diabetic retinopathy market include Intas Pharmaceuticals Limited, Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc., Allergan Plc, Regeneron Pharmaceuticals, Inc., Merck KGaA, Cipla, Ltd., Genentech, Inc. (Roche Holdings), Novartis AG, and Pfizer, Inc.

Heightening Cases of Long-term Diabetes to Influence Growth of Proliferative Diabetic Retinopathy Market

Diabetes has been a problem for many decades and causes great loss of lives throughout the year. A large number of people are diagnosed with diabetes. According to the International Diabetes Federation, nearly 463 mn adults were living with diabetes and the number will rise to 700 mn by 2045. Diabetes brings a wide range of diseases and disorders.

  • Diabetic retinopathy is one of the vital complications associated with long-term diabetes. Proliferative diabetic retinopathy is a sub-type of diabetic retinopathy with a larger case-rate worldwide. Thus, the growing threat of proliferative diabetic retinopathy will invite promising growth for the proliferative diabetic retinopathy market during the forecast period of 2017-2026.
  • The rising numbers across the geriatric population have brought tremendous growth opportunities for the proliferative diabetic retinopathy market. The geriatric populace is more susceptible to chronic diseases and thus, this aspect may further enhance the growth prospects of the proliferative diabetic retinopathy market.
  • The availability of advanced healthcare technologies and minimally invasive laser technique will have a massive impact on the growth of the proliferative diabetic retinopathy market. In addition, the rise in the disposable income of consumers will strengthen the growth of the proliferative diabetic retinopathy market to a great extent. Escalating concerns regarding vision loss will further help the proliferative diabetic retinopathy market to gain profitable growth.
  • The novel coronavirus pandemic has affected the proliferative diabetic retinopathy market to a certain extent. The outbreak has completely changed the growth dynamics of various businesses and sectors. The border restrictions and the stringent stay-at-home orders have disrupted the supply chain mechanisms extensively. Thus, all these aspects have negatively influenced the growth of the proliferative diabetic retinopathy market. However, the easing of lockdown restrictions presents a good opportunity for the players in the proliferative diabetic retinopathy market to regain lost growth.

Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The diabetic pandemic has threatened overwhelming resources and increasing incidences of blindness, which in turn has necessitated the development of actionable programs for diagnosis and treatment of the disease as well as the diseases caused as a consequence of diabetes such as proliferative diabetic retinopathy.

The global proliferative diabetic retinopathy market has been thoroughly analyzed in the latest research report developed by Transparency Market Research, which issues in-depth insights on prominent factors impacting growth of the market. Growth prospects offered in the report are assessed for the period between 2017 and 2026, and the historical analysis on the market has been delivered for the period between 2012 and 2016.

The report issues analysis on key threats, opportunities, restrains and drivers of the proliferative diabetic retinopathy market’s growth, coupled with in-depth study on their likely influences on the market. Valuable qualitative information offered in the report can enable readers in acquiring a thorough understanding of impactful market dynamics. Apart from a comprehensive analysis on influential market dynamics, the report also encompasses the raw material sourcing strategies, pricing analysis, cost structure, and supply chain analysis on the global proliferative diabetic retinopathy market.

The report comprises a detailed segmentation-wise analysis on the global proliferative diabetic retinopathy market, which provides readers with better understanding about lucrative and sluggish avenues for the market expansion. The global market for proliferative diabetic retinopathy has been assessed across a range of segments viz. drug class, mode of administration, distribution channel, and region. Geographically, the market has been branched into Asia-Pacific excluding Japan, Latin America, Japan, Middle East & Africa, Europe, and North America.

TMR’s report on the global proliferative diabetic retinopathy market is expected to be beneficial for proliferative diabetic retinopathy drug manufacturers, as existing players can leverage the intelligence offered for making better business decisions. Players evaluating a market entry will gain necessary insights through this report. This report is expected to serve as pragmatic and comprehensive source of knowledge and insights, which will help key stakeholders to formulate their future business plans.

Detailed Assessment of Competition Landscape & Exhaustive Research Methodology

The report also encompasses an exhaustive chapter on the proliferative diabetic retinopathy market’s competition landscape, which gives a detailed profiling of key companies that offer significant contribution to the market growth. Along with in-depth discussion and analysis on the business and product development strategies of the market players comprised, the report also sheds light on financial performance of these companies, coupled with their recent developments over the past couple of years. This concluding chapter of the report is of high value to the report readers, as they can attain actionable insights on novel developmental and growth strategies employed by the market players. This will further help them in gauging their respective positioning in this highly competitive market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Market Taxonomy

Region

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Drug Class

  • Anti-VEGF Agents
  • Corticosteroids

Mode of Administration

  • Injectables
  • Oral
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Global Economic Outlook

2. Global Proliferative Diabetic Retinopathy Market - Executive Summary

3. Global Proliferative Diabetic Retinopathy Market Overview
     3.1. Introduction
            3.1.1. Global Proliferative Diabetic Retinopathy Market Taxonomy
            3.1.2. Global Proliferative Diabetic Retinopathy Market Definition
     3.2. Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Forecast, 2012-2026
            3.2.1. Global Proliferative Diabetic Retinopathy Market Y-o-Y Growth
     3.3. Global Proliferative Diabetic Retinopathy Market Dynamics
     3.4. Supply Chain
     3.5. Cost Structure
     3.6. Average Pricing Analysis
     3.7. Forecast Scenario
     3.8. Parent Market Overview
     3.9. Product Approvals in Proliferative Diabetic Retinopathy
     3.10. PATENT Analysis
     3.11. Porter's Five Forces Analysis
     3.12. Epidemiology
     3.13. Investment Feasibility Index
     3.14. Market Competition Structure
     3.15. PEST Analysis
     3.16. Market Positioning & Behavior Assessment
     3.17. List of Distributors
     3.18. Key Participants Market Presence (Intensity Map) By Region

4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast 2012-2026
     4.1. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Drug Class, 2012-2026
            4.1.1. Anti-VEGF Agents Market Size and Forecast, 2012-2026
                     4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                     4.1.1.2. Market Share Comparison, By Region
                     4.1.1.3. Y-o-Y growth Comparison, By Region
            4.1.2. Corticosteroids Market Size and Forecast, 2012-2026
                     4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                     4.1.2.2. Market Share Comparison, By Region
                     4.1.2.3. Y-o-Y growth Comparison, By Region
     4.2. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Mode of Administration, 2012-2026
            4.2.1. Injectables Market Size and Forecast, 2012-2026
                     4.2.1.1. Revenue (US$ Mn) Comparison, By Region
                     4.2.1.2. Market Share Comparison, By Region
                     4.2.1.3. Y-o-Y growth Comparison, By Region
            4.2.2. Oral Market Size and Forecast, 2012-2026
                     4.2.2.1. Revenue (US$ Mn) Comparison, By Region
                     4.2.2.2. Market Share Comparison, By Region
                     4.2.2.3. Y-o-Y growth Comparison, By Region
            4.2.3. Others Market Size and Forecast, 2012-2026
                     4.2.3.1. Revenue (US$ Mn) Comparison, By Region
                     4.2.3.2. Market Share Comparison, By Region
                     4.2.3.3. Y-o-Y growth Comparison, By Region
     4.3. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Distribution Channel, 2012-2026
            4.3.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
                     4.3.1.1. Revenue (US$ Mn) Comparison, By Region
                     4.3.1.2. Market Share Comparison, By Region
                     4.3.1.3. Y-o-Y growth Comparison, By Region
            4.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
                     4.3.2.1. Revenue (US$ Mn) Comparison, By Region
                     4.3.2.2. Market Share Comparison, By Region
                     4.3.2.3. Y-o-Y growth Comparison, By Region
            4.3.3. Online Pharmacies Market Size and Forecast, 2012-2026
                     4.3.3.1. Revenue (US$ Mn) Comparison, By Region
                     4.3.3.2. Market Share Comparison, By Region
                     4.3.3.3. Y-o-Y growth Comparison, By Region

5. North America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     5.1. North America Outlook
     5.2. North America Parent Market Outlook
     5.3. North America Target Market Outlook
     5.4. Revenue (US$ Mn) Comparison, By Country
            5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
            5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
     5.5. Revenue (US$ Mn) Comparison, By Drug Class
     5.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     5.7. Revenue (US$ Mn) Comparison, By Distribution Channel

6. Latin America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     6.1. Latin America Outlook
     6.2. Latin America Parent Market Outlook
     6.3. Latin America Target Market Outlook
     6.4. Revenue (US$ Mn) Comparison, By Country
            6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
            6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
            6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
     6.5. Revenue (US$ Mn) Comparison, By Drug Class
     6.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     6.7. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Europe Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     7.1. Europe Outlook
     7.2. Europe Parent Market Outlook
     7.3. Europe Target Market Outlook
     7.4. Revenue (US$ Mn) Comparison, By Country
            7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
            7.4.2. U.K. Market Size and Forecast (US$ Mn), 2012-2026
            7.4.3. Spain Market Size and Forecast (US$ Mn), 2012-2026
            7.4.4. France Market Size and Forecast (US$ Mn), 2012-2026
            7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
            7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
     7.5. Revenue (US$ Mn) Comparison, By Drug Class
     7.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     7.7. Revenue (US$ Mn) Comparison, By Distribution Channel

8. Japan Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     8.1. Japan Outlook
     8.2. Japan Parent Market Outlook
     8.3. Japan Target Market Outlook
     8.4. Japan  Market Size and Forecast (US$ Mn), 2012-2026
     8.5. Revenue (US$ Mn) Comparison, By Drug Class
     8.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     8.7. Revenue (US$ Mn) Comparison, By Distribution Channel

9. APEJ Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     9.1. APEJ Outlook
     9.2. APEJ Parent Market Outlook
     9.3. APEJ Target Market Outlook
     9.4. Revenue (US$ Mn) Comparison, By Country
            9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
            9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
            9.4.3. Malaysia Market Size and Forecast (US$ Mn), 2012-2026
            9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
            9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
            9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
     9.5. Revenue (US$ Mn) Comparison, By Drug Class
     9.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     9.7. Revenue (US$ Mn) Comparison, By Distribution Channel

10. MEA Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
     10.1. MEA Outlook
     10.2. MEA Parent Market Outlook
     10.3. MEA Target Market Outlook
     10.4. Revenue (US$ Mn) Comparison, By Country
            10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
            10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
            10.4.3. Israel Market Size and Forecast (US$ Mn), 2012-2026
            10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
     10.5. Revenue (US$ Mn) Comparison, By Drug Class
     10.6. Revenue (US$ Mn) Comparison, By Mode of Administration
     10.7. Revenue (US$ Mn) Comparison, By Distribution Channel

11. Global Proliferative Diabetic Retinopathy Market Company Share, Competition Landscape and Company Profiles
     11.1. Global Proliferative Diabetic Retinopathy Market - Company Share Analysis
     11.2. Global Proliferative Diabetic Retinopathy Market - Competition Landscape
     11.3. Global Proliferative Diabetic Retinopathy Market - Company Profiles
            11.3.1. Genentech, Inc. (Roche Holdings)
            11.3.2. Novartis AG
            11.3.3. Regeneron Pharmaceuticals, Inc.
            11.3.4. Pfizer, Inc.
            11.3.5. Merck KGaA
            11.3.6. Cipla, Ltd.
            11.3.7. Allergan Plc
            11.3.8. Valeant Pharmaceuticals International, Inc.
            11.3.9. Santen Pharmaceutical Co., Ltd.
            11.3.10. Alimera Sciences, Inc.
            11.3.11. Intas Pharmaceuticals Limited

12. Global Proliferative Diabetic Retinopathy Market - Key Takeaways

13. Research Methodology

14. Disclaimer

 

List of Table

TABLE 1 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2012-2017
TABLE 2 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2018-2026
TABLE 3 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Anti-VEGF Agents Segment Market Share, By Region 2012-2017
TABLE 7 Global Anti-VEGF Agents Segment Market Share, By Region 2018-2026
TABLE 8 Global Anti-VEGF Agents Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Corticosteroids Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Corticosteroids Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Corticosteroids Segment Market Share, By Region 2012-2017
TABLE 12 Global Corticosteroids Segment Market Share, By Region 2018-2026
TABLE 13 Global Corticosteroids Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Injectables Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Injectables Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Injectables Segment Market Share, By Region 2012-2017
TABLE 17 Global Injectables Segment Market Share, By Region 2018-2026
TABLE 18 Global Injectables Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Oral Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Oral Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Oral Segment Market Share, By Region 2012-2017
TABLE 22 Global Oral Segment Market Share, By Region 2018-2026
TABLE 23 Global Oral Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Others Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Others Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Others Segment Market Share, By Region 2012-2017
TABLE 27 Global Others Segment Market Share, By Region 2018-2026
TABLE 28 Global Others Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 32 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 33 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 37 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 38 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Online Pharmacies Segment Market Share, By Region 2012-2017
TABLE 42 Global Online Pharmacies Segment Market Share, By Region 2018-2026
TABLE 43 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 44 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 45 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 46 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 47 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 48 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 49 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 50 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 51 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 52 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 53 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 54 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 55 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 56 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 57 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 58 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 59 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 60 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 61 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 62 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 63 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 64 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 65 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 66 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 67 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 68 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 69 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 70 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 71 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 72 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 73 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 74 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 75 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 76 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 77 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 78 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 79 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 80 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 81 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 82 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 83 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 84 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 85 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 86 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 87 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 88 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 89 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 90 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 91 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026

 

List of Figure

FIG. 1 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2012-2017
FIG. 2 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast, 2018-2026
FIG. 3 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) and Y-o-Y, 2017-2026
FIG. 4 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 5 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 6 Global Anti-VEGF Agents Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 7 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 8 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 9 Global Corticosteroids Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 10 Global Injectables Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 11 Global Injectables Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 12 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 13 Global Oral Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 14 Global Oral Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 15 Global Oral Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 16 Global Others Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 17 Global Others Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 18 Global Others Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 19 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 20 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 21 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 22 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 23 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 24 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 25 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 26 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 27 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 28 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 29 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 30 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 31 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 32 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 33 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 34 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 35 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 36 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 37 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 38 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 39 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 40 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 41 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 42 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 43 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 44 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 45 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 46 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 47 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 48 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 49 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 50 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 51 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 52 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 53 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 54 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 55 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 56 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 57 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 58 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 59 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 60 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 61 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 62 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 63 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 64 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 65 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 66 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 67 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 68 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
FIG. 69 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
FIG. 70 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 71 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 72 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 73 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 74 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 75 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Proliferative Diabetic Retinopathy Market